Search - tctmd.com

Displaying 261 - 280 of 281

Sort: Relevancy | Date

News Industry News

Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

November 29, 2015

News Daily News

首个 NOAC 逆转剂 Idarucizumab 获批；不太可能耽误介入治疗

October 26, 2015

News Daily News

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

October 26, 2015

News Daily News

Aprobado el Idarucizumab, Primer Antídoto de NOAC; El Deseo es no Demorar las Intervenciones

October 26, 2015

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding Focused Commentary

Presentation TCT 2015

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding Focused Commentary

Presenter: Martin B. Leon, Mark Reisman, Chet Rihal, Martin W Bergmann

October 15, 2015

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding

Presentation TCT 2015

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding

Presenter: Martin B. Leon, Mark Reisman, Chet Rihal, Brij Maini

October 15, 2015

Data Gaps and Future Trial Pathways: Possible Study Designs for New Devices, Anticoagulation Ineligible Patients, and Comparative NOAC Data

Presentation TCT 2015

Data Gaps and Future Trial Pathways: Possible Study Designs for New Devices, Anticoagulation Ineligible Patients, and Comparative NOAC Data

Presenter: Nicole Ibrahim, Saibal Kar, Zoltan G. Turi

October 14, 2015

Which NOAC for Which Patient?

Presentation TCT 2015

Which NOAC for Which Patient?

Presenter: David R. Holmes Jr., Vivek Y. Reddy, Christopher B. Granger

October 11, 2015

News Industry News

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

September 25, 2015

News Industry News

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

July 13, 2015

News Industry News

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

June 26, 2015

News Industry News

One-Year Outcomes Data on Stroke Prevention in Patients With Newly Diagnosed Atrial Fibrillation (AF) to Be Presented at ISTH 2015

June 18, 2015

News Industry News

Patients Undergoing Catheter Ablation Presented at Heart Rhythm 2015

May 15, 2015

News Daily News

药剂师有助于大幅改善达比加群酯依从性

April 17, 2015

News Daily News

Pharmacists May Help Ameliorate Substantial Variation in Dabigatran Adherence

April 17, 2015

How to Interpret Hypercoagulable Laboratory Results while your patient is on one of the NOACs

Presentation VEINS 2014

How to Interpret Hypercoagulable Laboratory Results while your patient is on one of the NOACs

Presenter: John R. Bartholomew

October 10, 2014

Prophylaxis and Medical Management of Venous Disease: Monitoring and Reversing NOACs

Presentation VEINS 2014

Prophylaxis and Medical Management of Venous Disease: Monitoring and Reversing NOACs

Presenter: James B. Froehlich

October 10, 2014

Comparative Analysis of Warfarin and the NOACs: Differentiating Properties, Risks, and Benefits

Presentation TCT 2014

Comparative Analysis of Warfarin and the NOACs: Differentiating Properties, Risks, and Benefits

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Jonathan L. Halperin

September 15, 2014

Bleeding and Stroke Risk Assessment in Atrial Fibrillation: Choosing between Warfarin, NOACS, Antiplatelets, or Nothing?

Presentation TCT 2014

Bleeding and Stroke Risk Assessment in Atrial Fibrillation: Choosing between Warfarin, NOACS, Antiplatelets, or Nothing?

Presenter: Matthew J. Price, Michael D. Ezekowitz

September 15, 2014

News Industry News

New registry data highlight substantial global differences in stroke prevention for patients with an irregular heart beat

May 07, 2014

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.